TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573):
Sucampo Pharmaceuticals, Inc. (“Sucampo”) and Takeda Pharmaceutical Company Limited (Takeda) announced that on October 17, 2014, they have entered into a global license, development, commercialization and supply agreement for AMITIZA® (lubiprostone). (See Sucampo press release)
Through this agreement, Takeda expanded its exclusive rights beyond the United States (U.S.) and Canada to further develop and commercialize AMITIZA® in all global markets, except Japan and the People’s Republic of China.
R-Tech Ueno has a global exclusive manufacturing and supply right to AMITIZA®.
As a result of the above, there are no changes to the business forecasts throughout the year that were published on May 14, 2014.
For full details of the press release, please visit:
http://www.rtechueno.com/en/investor/press/documents/141023_pr_en.pdf
